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a  b  s  t  r  a  c  t
Inﬂammatory bowel disease, which mainly involves Crohn’s disease and ulcerative recto-
colitis, is an inﬂammatory condition of the mucosa that can afﬂict any segment of the
gastrointestinal tract. Despite the fact that the existing therapies result in improvement in
patient’s symptomatology and quality of life, there is no curative treatment. Surgical treat-
ment  involves complex procedures associated with high morbidity and mortality rates. In
this context, cell therapy with stem cells has emerged as a treatment with broad poten-
tial  applicability. In this study, we intended to verify the efﬁcacy of transplantation of
adipose tissue-derived stem cells in rats with intestinal inﬂammation induced by trini-
trobenzenesulfonic acid. The cell population was isolated from the adipose tissue of inguinal
region of rats and processed for culture by mechanical dissociation. The animals were
evaluated with respect to clinical and biochemical aspects, as well as by macroscopic,
microscopic and histological analyses. In the experimental model of bowel inﬂammation
by  2,4,6-trinitrobenzenesulfonic acid, the infusion of adipose tissue signiﬁcantly reduced
the  presence of adhesions in the colon and adjacent organs and decreased the activity of
myeloperoxidase, a marker of neutrophil inﬁltration in the injured mucosa. The results sug-
gest that cell therapy with adipose tissue can promote and/or accelerate the regeneration of
damaged intestinal mucosa. It is concluded that the presence of adhesions and the deter-
mination of myeloperoxidase activity provide indications that adipose tissue can promote
and/or accelerate the regeneration of inﬂammatory bowel mucosa.©  2014 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. All
rights reserved.
 Study conducted at Department of Biological Sciences, Universidade Estadual Paulista (UNESP), Assis Campus, Assis, SP, Brazil.
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r  e  s  u  m  o
A Doenc¸a Inﬂamatória Intestinal (DII), consistindo principalmente da doenc¸a de Crohn e
retocolite ulcerativa, é uma condic¸ão inﬂamatória da mucosa que pode acometer qualquer
segmento do trato gastrointestinal. Apesar das terapias existentes resultarem na melhora
dos sintomas e da qualidade de vida dos pacientes, não há nenhum tratamento curativo.
O  tratamento cirúrgico envolve procedimentos complexos associados a altas taxas de mor-
bimortalidade. Neste contexto, a terapia celular com células-tronco desponta como opc¸ão
de  tratamento potencialmente promissora. Em func¸ão destes aspectos, pretendeu-se, no
presente estudo, veriﬁcar a eﬁcácia do transplante de células-tronco derivadas do tecido
adiposo (ASC) em ratos com inﬂamac¸ão intestinal induzida por ácido trinitrobenzenosul-
fonico (TNBS). As ASCs foram obtidas por dissociac¸ão mecânica do tecido adiposo da região
inguinal de ratos e processadas para cultivo. Os animais foram avaliados, considerando-se
os  aspectos clínicos e bioquímicos, além de análises macroscópica, microscópica e his-
tológica. No modelo de inﬂamac¸ão intestinal induzida por TNBS, a infusão de ASCs reduziu
signiﬁcativamente a presenc¸a de aderências entre o cólon e órgãos adjacentes, bem como
diminuiu a atividade da mieloperoxidase (MPO), um marcador da inﬁltrac¸ão de neutróﬁlos
na mucosa lesada. Os resultados obtidos permitem concluir que a terapia celular com ASCs
pode promover e/ou acelerar o processo de regenerac¸ão da mucosa intestinal inﬂamada.
©  2014 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.




























nﬂammatory bowel disease (IBD) comprises two nosological
ntities of chronic and recurrent nature: Crohn’s disease (CD)
nd ulcerative rectocolitis (URC).1 CD is a transmural inﬂam-
atory condition of mucosa that can affect any segment of the
astrointestinal tract.2,3 Unlike CD, URC is a disease character-
zed by diffuse inﬂammation of colonic mucosa. URC affects
he rectum (95% of cases) and proximal portions of the colon,
n a symmetric and continuous manner.4,5
Despite the introduction of new clinical therapeutic
pproaches and their contribution to improve the quality of
ife of patients with IBD and/or in the prevention of recurrence,
here is no deﬁnitive clinical curative treatment. The surgical
reatment, in turn, involves complex procedures associated
ith high rates of morbidity and mortality and postoperative
omplications.6,7
Several studies have shown that mesenchymal stem cells
MSC) may be involved in tissue regeneration, since they
ave the ability to modulate the immune responses of pro-
nﬂammatory cells to induce an environment with a more
olerant phenotype to inﬂammation.8–11 Furthermore, it is
roposed that these cells act in regulating the immune system
n inﬂammatory tissues, putting into action proinﬂammatory
ytokines and the secretion of chemokines.12 Thus, it can be
ostulated that MSC  could exert an anti-inﬂammatory action
n response to the induction of injury in experimental mod-
ls in vivo and, thus, acting as a potential therapeutic agent in
nﬂammatory diseases such as URC and CD.
In light of this, in this study we intended to verify the
ffectiveness of transplantation of MSC  derived from adiposetissue (ASC) in rats with intestinal inﬂammation induced by
trinitrobenzenesulfonic acid (TNBS). In addition, with this
approach we  intend to shed light on pathophysiological
aspects of IBD, as well as to suggest and evaluate the effec-
tiveness of new alternative therapies.
Method
Animals
In this study, Wistar albino rats (Rattus norvegicus), raised in the
Central Bioterium, UNESP – campus of Assis, were used under
controlled temperature (22 ◦C) and lighting (12 h of light/12 h of
darkness) conditions and fed with a solid diet supplemented
with Vitagold® (Tortuga, Sao Paulo, Brazil).
Experimental  groups
The animals were divided into the following experimental
groups: blank (healthy animals), control (animals with TNBS-
induced bowel inﬂammation and treated with phosphate–PBS
buffer) and treated (animals with TNBS-induced bowel inﬂam-
mation and treated with mesenchymal stem cells) groups.
Isolation  by  mechanical  dissociation  and  culture  of
adipose  tissue-derived  stem  cells
The adipose tissue extracted from the groin of rats was
mechanically dissociated with the help of two  L-shaped
syringe needles (BDTM, New Jersey, USA) in RPMI 1640
medium (Gibco®, New York, USA) supplemented with 2%
 j). 2 22  j coloproctol (rio
antibiotic/antimycotic (Gibco®, New York, USA) for cell/tissue
separation. Then, the solution containing dissociated cells
was ﬁltered through a 70 m-ﬁlter (Cell Strainer – BD FalconTM,
New Jersey, USA) for separating cellular debris. The collected
material was centrifuged for 10 min  at 900 × g. Then, the cells
were seeded in ALPHA-MEM medium (Gibco®, New York, USA)
supplemented with 20% Fetal Calf Serum – FCS (Gibco®, New
York, USA) and 1% antibiotic/antimycotic to a ﬁnal concentra-
tion of 1 × 105 cells/cm2 and incubated at 37 ◦C in 5% CO2. Cells
were maintained in culture and, when a 60–80% conﬂuence in
relation to the culture dish area was reached, were dissociated
with TrypleTM (Gibco®, New York, USA).
In  vitro  differentiation  of  adipose  tissue-derived  stem  cells
In order to induce osteogenic, chondrogenic and adipogenic
differentiation, speciﬁc kits (StemPro® – Gibco®, New York,
USA) were used, according to manufacturer’s instructions.
The osteogenic differentiation was conﬁrmed by analysis of
the material stained with Alizarin Red S (Sigma–Aldrich®, St.
Louis, MO, USA), the chondrogenic differentiation with Alcian
Blue dye (Sigma–Aldrich®, St. Louis, MO, USA), and the adi-
pogenic differentiation with Oil Red O (Sigma–Aldrich®, St.
Louis, MO, USA).
Experimental  model  of  IBD
The induction of the bowel inﬂammatory process was per-
formed by the method described by Morris et al.,13 with minor
modiﬁcations. 2,4,6-Trinitrobenzenesulfonic acid – TNBS
(Sigma–Aldrich®, St. Louis, MO, USA) was ﬁrst lyophilized and
subsequently prepared to obtain a solution of 40 mg/mL  in
50% ethanol (v/v). Bowel inﬂammatory process induction was
performed by intracolonic administration of 0.25 mL  TNBS
solution at a point 8 cm from the rectum. The animals in the
blank group underwent the same procedure, but with admin-
istration of PBS replacing TNBS. All animals were sacriﬁced
seven days after the induction of IBD.
Cell  transplantation
The cell infusion was performed by intravenous route (tail
vein). In the treated group, 1 mL  of the cell solution diluted
in PBS at a concentration of 1 × 107 cells/mL was infused. The
control group received a similar treatment; however, only PBS
was infused.
Evaluation  of  anti-inﬂammatory  bowel  activity
The animals were evaluated, considering food consumption,
body weight and onset of diarrheal stools. At the end of the
experiment, the colons were extracted and analyzed for bowel
damage.Macroscopic  analysis
The weight and length of the colon and presence of adhe-
sions in the bowel and surrounding organs were evaluated. An0 1 5;3  5(1):20–27
analysis of severity and extent of bowel injury, according to a
scale previously described by Bell et al.,14 was also performed.
Biochemical  determinations
The determination of total glutathione (GSH) content was per-
formed according to the method described by Anderson,15
and the determination of myeloperoxidase (MPO) activity in
rat colon fragments was performed by the method of Krawisz
et al.16
Histologic  analysis
Immediately after the macroscopic evaluation of the colonic
inﬂammatory process, tissue samples (0.5 mm)  adjacent to the
injured area were collected for histological processing. These
samples were placed in histological cassettes, ﬁxed in 4% for-
malin and stained with hematoxylin–eosin (HE).
Statistical  analysis
Results were expressed as mean ± standard deviation. Differ-
ences between means were tested by analysis of variance
(ANOVA), followed by tests of signiﬁcance. Nonparametric
data (scores) were expressed as median and analyzed by
Kruscal–Wallis test. Discontinuous data were analyzed by chi-
squared (X2) test. Statistical signiﬁcance was considered when
p < 0.05.
Ethical  aspects
This study was approved by the Ethics Committee on the Use
of Animals (CEUA), Universidade Estadual Paulista – UNESP,
campus of Assis (Registration No. 012/2011).
Results
Culture  and  characterization  of  adipose  tissue-derived
stem  cells
As shown in Fig. 1A, on day 7 of culture a signiﬁcant population
of cells with an elongated, fusiform appearance was observed.
A 70–80% conﬂuence was achieved around the 11th day of cul-
ture (Fig. 1B). After the ﬁrst dissociation process with Tryple®
(Gibco®, New York, USA), the cell growth became faster,
because the 70–80% conﬂuence level was reached within 3–4
days. It was also observed that, after the third passage, the
culture had assumed the appearance of a uniform monolayer
of spindle cells (Fig. 1C), indicating that probably there was
no contamination with non-adherent cells, such as mature
adipocytes and erythrocytes.
To verify whether the cells isolated from adipose tissue
(ASC) met  the requirements established by the Interna-
tional Society of Cellular Therapy for validation of MSC,17
in vitro differentiation tests with ASC to obtain chondrocytes,
osteocytes and adipocytes were performed. Fig. 2B shows
the chondrogenic differentiation. The blue color is indica-
tive of proteoglycan synthesis by chondrocytes. Osteogenesis
was conﬁrmed by osteoblasts and osteocytes’ bone matrix
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Fig. 1 – Behavior of adipose tissue-derived stem cells at different periods of culture. (A) Primary culture (7 days); (B) after 11
days (70–80% conﬂuence); and (C) homogeneous monolayer of ce
Fig. 2 – Differentiation of ASC into chondrocytes, osteocytes
and adipocytes. (A) Culture of ASC in the absence of an
induction medium (20×); (B) proteoglycans synthesized by









Presence of adhesions in the intestine and surrounding organsatrix stained with Alizarin Red S (40×); and (D) lipid
acuoles stained with Oil Red O (40×).
taining (Fig. 2C). Finally, the differentiation of ASC into
dipocytes was proven. As seen in Fig. 2D, lipid vacuoles are
tained in red.
valuation  of  bowel  anti-inﬂammatory  activityhe food intake showed that the average consumption by
ealthy animals was higher, when compared with control
Table 1 – Macroscopic parameters from treatment with adipose
of inﬂammatory bowel disease, by administering an alcoholic s
Group Score (0–10)a Injury extent (cm)b Weig
Blank 0a 0a
Control–PBS 7 (5–9)b 3.70 ± 0.741b
Treated with ASC 6.5 (4–9)b 3.51 ± 0.415b
a The score values are expressed as median (range).
b Injury extent and colonic weight/length ratio are expressed as mean ± S
c Adherence was analyzed by X2 test. Values without letters in common slls with ﬁbroblastoid aspect (third passage).
group animals. The consumption of blank group animals
was statistically different, compared to control and treated
groups. However, there was no statistically signiﬁcant differ-
ence between control and treated groups.
The daily body weight evaluation showed that, due to the
reduction of food consumption, there was a decrease in body
weight of animals subjected to the administration of the alco-
holic solution of TNBS. The mean delta body weight of blank
group showed statistically signiﬁcant difference, when com-
pared to control and treated groups. However, there was no
statistically signiﬁcant difference between treated and control
groups.
The presence of diarrheal stools was daily monitored in
all groups of animals. With respect to control group animals,
an incidence of 100% was observed, whereas in treated group
animals the incidence was 90%. An analysis of the results
showed no statistically signiﬁcant difference between control
and treated groups.
Macroscopic  evaluation
Colon  weight/length  (W/L)
There is a relationship for colonic injury resulting from
inﬂammation, and this can be quantitatively expressed by an
increase in colonic weight/length ratio (W/L in mg/cm). With
respect to the results presented in Table 1, we noted that there
was no statistically signiﬁcant difference in relation to colonic
W/L between control and treated groups.
Adhesionsis also considered a characteristic feature of bowel mucosa
inﬂammation. Table 1 shows 83.33% of adhesion in control
group animals and 20% in ASC-treated animals. A statistically
 tissue-derived stem cells (ASC) in an experimental model
olution of TNBS.
ht/length ratio (mg/cm)b Adherence (%)c
106.77 ± 3.241a 0a
269.57 ± 43.851b 83.33b
199.36 ± 27.85b 20c
EM (standard error of the mean).
how statistically signiﬁcant difference at p < 0.05.



























Fig. 3 – Assessment of the activity of myeloperoxidase
(MPO) in intestinal mucosa of an inﬂammatory bowel
disease animal model. Data are expressed as mean ± SEM.24  j coloproctol (rio
signiﬁcant difference between control and treated groups was
found.
Severity  and  extent  of  bowel  injury
The administration of TNBS in control group animals triggered
an inﬂammatory process characterized by lesions along the
colon, between 1.20 and 5.50 cm in length and a score between
5 and 9 (Table 1). The results show no statistically signiﬁcant
difference in relation to the lesion length and its score among
PBS–control group animals versus ASC-treated animals.
Biochemical  analysis
The animals treated with the alcoholic solution of TNBS
showed a statistically signiﬁcant difference in regard to a
reduction in glutathione levels, when compared to blank
group animals. Although GSH levels were higher in treated
animals, there was no signiﬁcant difference when confronting
the results among PBS-treated versus ASC-treated animals.
In the case of myeloperoxidase (MPO) activity, it was found
that the treatment with adipose tissue-derived stem cells
resulted in a statistically signiﬁcant difference in terms of
enzyme activity, when compared to control group, as can be
seen in Fig. 3.
Histological  analysisFig. 4A shows the normal colonic cytoarchitecture of a healthy
animal, where the cells are intact, and mucosal, submu-
cosal and muscularis mucosa layers and their dimensions are
Fig. 4 – Photomicrograph of colonic mucosa of rats after ulcerativ
solution of TNBS. The sections were  stained with hematoxylin–e
rat colon (10×); (B) control group–PBS: severe ulceration and subm
treated with ASC: submucosal inﬁltration of inﬂammatory cells (
and (C) the white arrows indicate an inﬂammatory cell inﬁltrate.Values without letters in common differ at p < 0.05.
clearly identiﬁed, without any kind of morphological change.
Fig. 4B depicts the colon of an animal with TNBS-induced
inﬂammatory process, characterized by mucosal disruption
and the presence of abnormal cells as to form, size and
number compared to healthy animals. Additionally, a large
submucosal cell inﬁltrate, typical of neutrophil migration due
to colonic inﬂammation, is perceived. Fig. 4C depicts the colon
e colitis induction by administration of an alcoholic
osin. (A) Non-colitic group (blank): histology of a non-colitic
ucosal inﬁltration of inﬂammatory cells (10×);  (C) group
5×). (B) The black arrow indicates submucosal ulceration





















































ij coloproctol (rio j
f an animal undergoing treatment with ASC, where a large
ellular inﬁltrate due to TNBS-induced colonic inﬂammation
s noted. However, there is no mucosal disruption – an occur-
ence clearly seen in PBS-treated animals. The mucosal cells
re not signiﬁcantly altered in shape, and a clear recovery of
olonic cytoarchitecture can be perceived.
iscussion  and  conclusion
tem cells derived from adipose tissue (ASC) have been used
xperimentally as a potentially promising alternative ther-
py in a number of diseases. The therapeutic effect of stem
ells is attributable to a probable immunomodulatory action,
ith suppression or inhibition of the inﬂammatory process,
s well as by angiogenesis stimulation.8–12,18 In this context,
BD can be included in the group of diseases that can ben-
ﬁt from cell therapy with stem cells. The ASC used in this
tudy was identiﬁed as a population of elongated, fusiform
ells, a characteristic feature of MSC  and showing plastic sur-
ace adherence. Furthermore, ASC presented, when in speciﬁc
onditions of induction, the functional property of differen-
iation in vitro in chondrogenic, osteogenic and adipogenic
ineages, consistent with validation criteria reported by other
uthors and deﬁned by the International Society for Cellular
herapy.11,17
The enzymatic digestion by using collagenase is currently
he most widely used procedure for obtaining and isolat-
ng ASC.18,19 In this study, we  used an innovative and novel
echnique of mechanical dissociation for ASC isolation and
ulture. It should be emphasized that the mechanical dissoci-
tion makes unnecessary the use of collagenase, maintaining
he efﬁciency of the process and being cheaper.
It is well established that one of the symptoms of patients
uffering IBD is a reduction in body weight, considering that
here is a decrease in food intake, besides the occurrence of
astrointestinal disturbances.20 A reduction in food intake,
ith consequent weight loss of the animals after the induc-
ion of IBD, was seen in colitic groups. However, it was found
hat food intake and decrease of body weight in ASC-treated
nimals were similar to those for control group animals.
ccording to Morris et al.,13 the IBD induction model by
NBS/ethanol produces intestinal wall ulceration and thick-
ning, without affecting signiﬁcantly the long-term weight
ncrease of animals. Thus, the need for a longer period for
estoration of normal food intake and, thus, body weight, is
nferred.
Commonly, diarrhea occurs with an inﬂammation of the
olon and small intestine, as a result from the action of inﬂam-
atory mediators in bowel epithelium.21 The occurrence of
his observation parameter, a characteristic feature of IBD, was
bserved in 90% of ASC-treated group animals, showing that,
fter 7 days of treatment, there is still a large amount of inﬂam-
atory mediators in the colon. These data raise the possibility
hat the period for assessing the effectiveness of cell therapy
s an alternative treatment for IBD should be extended beyond
he 7-day period adopted in this study.
Other indicators of severity and extent of injury resulting
rom IBD are: increase in weight and decrease in colonic length
n animals with bowel inﬂammation.11,13,22 There is a clear 5;3  5(1):20–27 25
difference in mean W/L  ratio, as the Table 1 shows. However,
there was no statistically signiﬁcant difference between ani-
mals treated with stem cells versus control animals (Table 1).
This effect is possibly due to the severe injury caused by
the administration of the alcoholic solution of TNBS, thereby
complicating the regenerating process of the injured mucosa.
Ando et al.11 reported that an injection of ASC directly beneath
the colon submucosa signiﬁcantly decreases the weight of the
inﬂamed colon. This is an indication that the location and
route of cell administration can inﬂuence the ﬁnal outcome
of a treatment, as previously reported by other authors.23,24 In
this study we  adopted an IV infusion route for ASC, so that
the divergence among the results of this study and of those
reported by Ando et al.11 could be related to the different infu-
sion route used in the study.
It is also possible to evaluate the intensity of IBD lesion
severity by its length and scoring.25 Table 1 shows that
the colonic damage caused by the infusion of alcohol/TNBS
was severe and extensive, making the recovery of intestinal
mucosa unlikely after 7 days of ASC infusion. In 2009, Wei
et al.26 compared the infusion of hematopoietic stem cells
(HSC), bone marrow stem cells (MSC) and a mixture of both cell
types in rats with TNBS-induced colitis after 7, 14 and 21 days.
The authors found that a decrease in the lesion score occurred
only on day 21. Furthermore, this result was only observed
in the group treated with a HSC/MSC combination. Thus, we
can infer that, due to the intensity and extent of the injury,
it would be necessary to increase the time period to evaluate
the stem cell performance with respect to the ability to reduce
inﬂammation and promote regeneration of the injured tissue.
Another point to be considered refers to the possibility of a
HSC/MSC co-infusion, considering that the synergistic effect
of these different cell types can act in a beneﬁcial way in the
treatment of a number of diseases.27,28
The presence of adhesions among the colon and sur-
rounding organs and/or tissues as a result of transmural
inﬂammation is a common feature of IBD, especially in CD.29
Table 1 shows the occurrence of a signiﬁcant reduction in the
incidence of adhesions in colitic animals and in ASC-treated
animals compared with control group animals, suggesting
that ASC acted as an agent protecting and/or reducing the
inﬂammatory process.
It can be noted that in experimental models of intestinal
inﬂammation by instillation of TNBS, GSH depletion resulting
from colonic inﬂammation occurred.22,25,30
It can be seen that the ASCs used did not present potential
to promote increased levels of GSH. It is noteworthy that no
study on humans or animal models with intestinal inﬂamma-
tion recording dosages of total glutathione levels after infusion
of stem cells has been published.
Among the biochemical analyzes, myeloperoxidase (MPO)
is an important tool for identifying the presence of neu-
trophilic inﬁltrates and for revealing an inﬂammatory
process as a result of the colonic inﬂammation. It is
known that MPO level reﬂects the quantity of neutrophils,
and a decrease in its activity reﬂects a decrease in the
16injured tissue inﬂammation. In the present study, it
was found that ASC-treated animals showed a statistically
signiﬁcant decrease in MPO activity compared to PBS-
treated animals (Fig. 3), showing that ASC can act as an
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anti-inﬂammatory agent, diminishing the damage caused by
TNBS administration.11,30
The presence of adhesions and the determination of
myeloperoxidase activity provide an indication that ASC have
the ability to promote and/or accelerate the regeneration pro-
cess in inﬂamed intestinal mucosae. However, methodological
adjustments should be included in future projects. Among
the propositions of readjustment, there should be included
an evaluation of the effectiveness of cell therapy for a longer
period of time; cell infusion by other routes of administration,
in addition to intravenous route; and feasibility of this therapy
through co-infusion of ASC in association with hematopoietic
stem cells (HSC).
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